<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>6639260</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmid">31320690</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmc">6639260</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="publisher-id">46859</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="doi">10.1038/s41598-019-46859-5</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Participant characteristics.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table 1</label><caption><p>Participant characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>CM</th><th>HC</th></tr></thead><tbody><tr><td>Participants (n)</td><td>28</td><td>28</td></tr><tr><td>Sex (m/f)</td><td>14/14</td><td>14/14</td></tr><tr><td>Age, years</td><td>66.5 ± 10.9 (44–79)</td><td>66.5 ± 11.0 (43–79)</td></tr><tr><td>Handedness (right/left)</td><td>26/2</td><td>26/2</td></tr><tr><td colspan="3">Medication</td></tr><tr><td>NSAIDs</td><td>2</td><td>0</td></tr><tr><td>Pregabalin</td><td>3</td><td>0</td></tr><tr><td>Tramadol/acetaminophen</td><td>1</td><td>0</td></tr><tr><td>Sedative-hypnotics</td><td>7</td><td>0</td></tr><tr><td>Change in the medication</td><td>1 (Stop of pregabalin)</td><td>NA</td></tr><tr><td>Disease duration (month)</td><td>36.4 ± 55.1 (3–246)</td><td>NA</td></tr></tbody></table><table-wrap-foot><p>CM, cervical myelopathy; HC, healthy control; m, male; f, female; NSAIDs, nonsteroidal anti-inflammatory agents; NA, not applicable.</p><p>Data are presented as mean ± SD (range) for continuous variables.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Participant characteristics.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>CM</th><th>HC</th></tr></thead><tbody><tr><td>Participants (n)</td><td>28</td><td>28</td></tr><tr><td>Sex (m/f)</td><td>14/14</td><td>14/14</td></tr><tr><td>Age, years</td><td>66.5 ± 10.9 (44–79)</td><td>66.5 ± 11.0 (43–79)</td></tr><tr><td>Handedness (right/left)</td><td>26/2</td><td>26/2</td></tr><tr><td colspan="3">Medication</td></tr><tr><td>NSAIDs</td><td>2</td><td>0</td></tr><tr><td>Pregabalin</td><td>3</td><td>0</td></tr><tr><td>Tramadol/acetaminophen</td><td>1</td><td>0</td></tr><tr><td>Sedative-hypnotics</td><td>7</td><td>0</td></tr><tr><td>Change in the medication</td><td>1 (Stop of pregabalin)</td><td>NA</td></tr><tr><td>Disease duration (month)</td><td>36.4 ± 55.1 (3–246)</td><td>NA</td></tr></tbody></table></div>CM, cervical myelopathy; HC, healthy control; m, male; f, female; NSAIDs, nonsteroidal anti-inflammatory agents; NA, not applicable.Data are presented as mean ± SD (range) for continuous variables.</transformed-table></extracted-table><extracted-table><table-id>Tab2</table-id><table-label>Table 2</table-label><table-caption>Patient clinical score.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table 2</label><caption><p>Patient clinical score.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Preop</th><th>Postop</th><th>p</th></tr></thead><tbody><tr><td colspan="4">JOA scores</td></tr><tr><td>    Upper-extremity motor score</td><td>2.2 ± 1.0 (−0.5–4)</td><td>3.4 ± 0.6 (2.5–4)</td><td>&lt;0.001</td></tr><tr><td>    Lower-extremity motor score</td><td>2.3 ± 0.9 (0.5–4)</td><td>2.9 ± 1.0 (1–4)</td><td>0.004</td></tr><tr><td>    Upper-extremity sensory score</td><td>1.0 ± 0.3 (0.5–1.5)</td><td>1.3 ± 0.4 (1–2)</td><td>0.001</td></tr><tr><td>    Trunk sensory score</td><td>1.7 ± 0.5 (1–2)</td><td>2.0 ± 0.1 (1.5–2)</td><td>0.004</td></tr><tr><td>    Lower-extremity motor score</td><td>1.2 ± 0.5 (0.5–2)</td><td>1.7 ± 0.4 (1–2)</td><td>&lt;0.001</td></tr><tr><td>    Sphincter score</td><td>2.4 ± 0.7 (1–3)</td><td>2.8 ± 0.5 (1–3)</td><td>0.009</td></tr><tr><td>    Total</td><td>10.8 ± 2.6 (4–15)</td><td>14.0 ± 2.0 (9–17)</td><td>&lt;0.001</td></tr><tr><td colspan="4">JOACMEQ scores</td></tr><tr><td>    Neck function</td><td>62.0 ± 27.4 (0–100)</td><td>77.9 ± 27.6 (10–100)</td><td>0.001</td></tr><tr><td>    Upper extremity function</td><td>71.1 ± 25.7 (5–100)</td><td>87.6 ± 15.7 (42–100)</td><td>0.028</td></tr><tr><td>    Lower extremity function</td><td>55.3 ± 29.8 (0–100)</td><td>73.5 ± 23.1 (36–100)</td><td>0.008</td></tr><tr><td>    Bladder function</td><td>70.4 ± 19.0 (38–100)</td><td>79.7 ± 17.9 (38–100)</td><td>&lt;0.001</td></tr><tr><td>    QOL</td><td>41.9 ± 24.0 (2–94)</td><td>53.4 ± 21.5 (16–97)</td><td>0.023</td></tr><tr><td>10-second test (lower side)*</td><td>15.6 ± 3.5 (11–21)</td><td>27.4 ± 7.8 (12–41)</td><td>0.004</td></tr><tr><td>Operative gain in 10-second test</td><td>NA</td><td>11.8 ± 6.6 (0–21)</td><td/></tr><tr><td colspan="4">VAS</td></tr><tr><td>    Pain or numbness in upper extremity (mm)</td><td>55.5 ± 28.0 (8–100)</td><td>45.9 ± 31.3 (0–100)</td><td>0.246</td></tr></tbody></table><table-wrap-foot><p>JOA, Japanese Orthopaedic Association; Japanese Orthopaedic Association Cervical Myelopathy Evaluation Questionnaire; QOL, quality of life; NA, not applicable; VAS, visual analogue scale.</p><p>Data are presented as mean ± SD (range) for continuous variables.</p><p>*The number for the 10-second test was represented by that on the lower side.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Patient clinical score.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Preop</th><th>Postop</th><th>p</th></tr></thead><tbody><tr><td colspan="4">JOA scores</td></tr><tr><td>    Upper-extremity motor score</td><td>2.2 ± 1.0 (−0.5–4)</td><td>3.4 ± 0.6 (2.5–4)</td><td>&lt;0.001</td></tr><tr><td>    Lower-extremity motor score</td><td>2.3 ± 0.9 (0.5–4)</td><td>2.9 ± 1.0 (1–4)</td><td>0.004</td></tr><tr><td>    Upper-extremity sensory score</td><td>1.0 ± 0.3 (0.5–1.5)</td><td>1.3 ± 0.4 (1–2)</td><td>0.001</td></tr><tr><td>    Trunk sensory score</td><td>1.7 ± 0.5 (1–2)</td><td>2.0 ± 0.1 (1.5–2)</td><td>0.004</td></tr><tr><td>    Lower-extremity motor score</td><td>1.2 ± 0.5 (0.5–2)</td><td>1.7 ± 0.4 (1–2)</td><td>&lt;0.001</td></tr><tr><td>    Sphincter score</td><td>2.4 ± 0.7 (1–3)</td><td>2.8 ± 0.5 (1–3)</td><td>0.009</td></tr><tr><td>    Total</td><td>10.8 ± 2.6 (4–15)</td><td>14.0 ± 2.0 (9–17)</td><td>&lt;0.001</td></tr><tr><td colspan="4">JOACMEQ scores</td></tr><tr><td>    Neck function</td><td>62.0 ± 27.4 (0–100)</td><td>77.9 ± 27.6 (10–100)</td><td>0.001</td></tr><tr><td>    Upper extremity function</td><td>71.1 ± 25.7 (5–100)</td><td>87.6 ± 15.7 (42–100)</td><td>0.028</td></tr><tr><td>    Lower extremity function</td><td>55.3 ± 29.8 (0–100)</td><td>73.5 ± 23.1 (36–100)</td><td>0.008</td></tr><tr><td>    Bladder function</td><td>70.4 ± 19.0 (38–100)</td><td>79.7 ± 17.9 (38–100)</td><td>&lt;0.001</td></tr><tr><td>    QOL</td><td>41.9 ± 24.0 (2–94)</td><td>53.4 ± 21.5 (16–97)</td><td>0.023</td></tr><tr><td>10-second test (lower side)*</td><td>15.6 ± 3.5 (11–21)</td><td>27.4 ± 7.8 (12–41)</td><td>0.004</td></tr><tr><td>Operative gain in 10-second test</td><td>NA</td><td>11.8 ± 6.6 (0–21)</td><td/></tr><tr><td colspan="4">VAS</td></tr><tr><td>    Pain or numbness in upper extremity (mm)</td><td>55.5 ± 28.0 (8–100)</td><td>45.9 ± 31.3 (0–100)</td><td>0.246</td></tr></tbody></table></div>JOA, Japanese Orthopaedic Association; Japanese Orthopaedic Association Cervical Myelopathy Evaluation Questionnaire; QOL, quality of life; NA, not applicable; VAS, visual analogue scale.Data are presented as mean ± SD (range) for continuous variables.*The number for the 10-second test was represented by that on the lower side.</transformed-table></extracted-table></extracted-tables-set>